Company profile

Theranexus specializes in the research and development of therapeutic products for the treatment of diseases affecting the central nervous system. At the end of 2017, the group had one product in Phase II clinical development (THN102; treatment of narcolepsy-related sleep-wake disorders and Parkinson's disease) and 2 products in preclinical development phase (THN101; treatment of neuropathic pain and THN201 for the treatment of neurocognitive disorders in Alzheimer's disease).

Source: Cofisem - Last Update: 09 May 2019
Key Executives
Chairman and Chief Executive Officer Franck Mouthon
Deputy CEO Mathieu Charveriat
Administrative & Finance Director Thierry Lambert
Source: Cofisem - Last Update: 09 May 2019
Key figures
Millenium 2018 2017 2016 2015
Net sales
Consumed purchases
Payroll 2,118 1,370 689 542
Operating profit -6,990 -2,719 -2,058 -1,116
Income tax -1,721 730 583 -605
Net income -5,301 -2,115 -1,587 -519
Net consolidated income (Group share) -5,301 -2,115 -1,587 -519
Fiscal year end 12.18 12.17 12.16 12.15
Length of fiscal year (month) 12 12 12 12
Currency & Unit EUR - thousands EUR - thousands EUR - thousands EUR - thousands
Account Standards
Source: Cofisem - Last Update: 09 May 2019
Shareholder information
Free float 32.90 %
Auriga Partners 14.50 %
Supernova Invest 13.90 %
Mathieu Charveriat 10.20 %
Franck Mouthon 10.20 %
Sofimac Régions 9.80 %
Kreaxi 5.10 %
Richard Platford 3.30 %
Employees 0.10 %
Source: Cofisem - Last Update: 06 May 2019

Address

Theranexus

Pépinière Laennec 60 Avenue Rockefeller
FR-69008 Lyon
France
Phone number: +33 (0)1 46 54 98 96
Fax: +33
Source: Cofisem - Last Update: 09 May 2019

Contact

LAMBERT THIERRY
Phone number: +33 1 46 54 98 96
Source: Cofisem - Last Update: 09 May 2019